Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21033475 | 0.83 | GAA (0.40) | RXFP1 | |
| SCHEMBL21033178 | 0.81 | RIPK1 (0.37) | RIPK1HDAC2RXFP1 | |
| SCHEMBL29852659 | 0.81 | LMNA (0.36) | HDAC2 | |
| SCHEMBL23645389 | 0.79 | TTR (0.37) | HDAC2SPR | |
| SCHEMBL21033242 | 0.78 | HDAC2 (0.34) | HDAC2RXFP1 | |
| SCHEMBL26299381 | 0.77 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL21033532 | 0.77 | HDAC2 (0.33) | RIPK1HDAC2 | |
| SCHEMBL21570164 | 0.77 | RIPK1 (0.34) | RIPK1SCD5SCDGPR35ALOX15 | |
| SCHEMBL21014288 | 0.75 | RIPK1 (0.33) | RIPK1HDAC2RXFP1 | |
| SCHEMBL3660427 | 0.75 | KDM4E (0.35) | HDAC2RXFP1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | RIPK1 1050/4885SCD5 522/4885SCD 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.